Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORLEX vs AMRIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Orlistat is a reversible inhibitor of gastric and pancreatic lipases, preventing the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. This reduces dietary fat absorption by approximately 30%.
Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.
Weight management (FDA approved for obesity, BMI ≥30 kg/m² or BMI ≥27 kg/m² with risk factors),Off-label: prevention of weight gain in type 2 diabetes
Treatment of spasticity due to multiple sclerosis, spinal cord injury, or other spinal cord disorders
Orally, 1-2 tablets (5-10 mg of hydrocodone equivalent) every 4-6 hours as needed for pain; maximum 12 tablets per day.
15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.
Terminal elimination half-life: 4-6 hours; in renal impairment, half-life can extend to >12 hours requiring dose adjustment.
Terminal elimination half-life approximately 32 hours (range 28–40 hours); clinically relevant for once-daily dosing in chronic muscle spasm
Primarily metabolized in the gastrointestinal wall and liver via hydrolysis; minimal systemic absorption. Main metabolites are M1 (4-member lactone ring hydrolysis) and M3 (M1 with a cleaved N-formyl leucine moiety).
Hepatic via deamination; primarily metabolized by monoamine oxidase B (MAO-B) to inactive metabolites.
Renal: 70% (as unchanged drug and metabolites); Biliary/Fecal: 30%
Renal: approximately 40% as unchanged drug and metabolites; biliary/fecal: minimal; total clearance: 2.5 L/min
99% primarily to albumin and alpha-1-acid glycoprotein
40–45% bound to serum proteins, primarily albumin
0.15-0.2 L/kg, indicating confinement to vascular space; correlates with high protein binding.
5–8 L/kg; suggests extensive tissue distribution, including skeletal muscle
Oral: 90-100% (extensive absorption); no significant first-pass metabolism.
Oral: 85–95% (extended-release formulation)
For GFR 30-59 m L/min: administer every 6-8 hours; GFR <30 m L/min: administer every 8-12 hours; avoid use in GFR <15 m L/min.
No specific dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min).
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25%; Child-Pugh Class C: avoid use.
Contraindicated in Child-Pugh class C. For Child-Pugh class A or B: initiate at 15 mg once daily; do not increase dose. Use with caution.
Children ≥2 years: 0.1-0.2 mg/kg hydrocodone equivalent orally every 4-6 hours as needed; maximum 10 mg per dose.
Safety and efficacy not established in pediatric patients under 12 years. For ages 12 and older, same as adult dosing.
Initiate at 50% of adult dose, titrate cautiously; monitor for respiratory depression and constipation.
Initiate at 15 mg once daily. Due to higher incidence of anticholinergic effects and falls, monitor closely; consider lower doses in frail elderly.
None
None
Hepatotoxicity (rare, but cases of severe liver injury reported),Cholelithiasis (increased risk due to rapid weight loss),Oxalate nephrolithiasis (increased urinary oxalate excretion),Fat-soluble vitamin deficiency (A, D, E, K; supplementation recommended),Gastrointestinal adverse effects (oily spotting, flatus with discharge, fecal urgency, steatorrhea),Interaction with cyclosporine, amiodarone, and antiepileptic drugs
Abrupt discontinuation may precipitate withdrawal syndrome including hallucinations, seizures, autonomic instability.,May cause sedation, dizziness, and muscle weakness; caution with activities requiring alertness.,Use with caution in patients with impaired renal function due to reduced clearance.,May exacerbate seizures in patients with epilepsy.,Avoid concomitant use with other CNS depressants.
Chronic malabsorption syndrome,Cholestasis,Pregnancy (weight loss is not recommended),Hypersensitivity to orlistat or any component
Hypersensitivity to amrix or baclofen.,Abrupt withdrawal is contraindicated; must be tapered.,Concomitant use with MAO inhibitors is contraindicated due to risk of hypertensive crisis.
Avoid alcohol completely; ethanol increases acetaminophen hepatotoxicity and potentiates CNS depression from hydrocodone. No specific food restrictions, but high-fat meals may delay absorption; take on an empty stomach for more consistent effects. Maintain adequate hydration to prevent constipation.
Avoid grapefruit and grapefruit juice during treatment as they may increase cyclobenzaprine levels. Taking AMRIX with or without food does not significantly affect absorption. Alcohol should be strictly avoided as it potentiates CNS depression.
ORLEX (codeine/acetaminophen) is contraindicated in all trimesters due to risk of neonatal opioid withdrawal syndrome and acetaminophen hepatotoxicity. First trimester: limited data but no major malformations reported. Second and third trimesters: chronic use may lead to fetal dependence and neonatal abstinence syndrome. During labor, codeine may cause respiratory depression in neonate.
Cyclobenzaprine (AMRIX) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but adequate well-controlled studies in pregnant women are lacking. Use only if clearly needed. First trimester: no specific teratogenic effects documented; second and third trimesters: avoid near term due to potential neonatal effects (e.g., sedation, withdrawal).
Codeine is excreted into breast milk with M/P ratio approximately 2.5. Risk of infant opioid toxicity, especially in ultra-rapid metabolizers; contraindicated in breastfeeding due to potential for infant respiratory depression and sedation. Acetaminophen is safe at low doses.
Cyclobenzaprine is excreted into human milk in small amounts. M/P ratio: not established. Use with caution in nursing mothers; monitor infant for sedation, poor feeding, or hypotonia.
Elimination half-life of codeine is decreased; effects may be reduced. Acetaminophen metabolism is increased. No standard dosing adjustment recommended due to lack of safety data; avoid use in pregnancy. If unavoidable, use lowest effective dose for shortest duration.
No specific dose adjustments are recommended based on pharmacokinetic changes in pregnancy; however, due to potential for increased clearance, lowest effective dose should be used. Avoid use during labor and delivery due to potential neonatal depression.
ORLEX is a combination of hydrocodone and acetaminophen; monitor for signs of acetaminophen hepatotoxicity, especially in patients with hepatic impairment or chronic alcohol use. Hydrocodone is a prodrug metabolized by CYP2D6; poor metabolizers may have reduced efficacy, while ultrarapid metabolizers risk toxicity. Use with caution in elderly or debilitated patients due to increased fall risk. Avoid concurrent use with other CNS depressants. Prescribe the lowest effective dose for the shortest duration.
AMRIX (cyclobenzaprine extended-release) should not be used longer than 2-3 weeks due to lack of evidence for efficacy in muscle spasm beyond that period. It has significant anticholinergic effects; avoid in patients with glaucoma, urinary retention, or those taking MAOIs. Do not crush or chew capsules; administer once daily at same time. Onset of action is delayed compared to immediate-release cyclobenzaprine.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush, chew, or break extended-release tablets.,Avoid alcohol while taking ORLEX; it increases risk of liver damage and sedation.,Do not drive or operate heavy machinery until you know how ORLEX affects you.,Discontinue use and seek emergency help if you experience signs of allergic reaction (rash, difficulty breathing) or serotonin syndrome (agitation, hallucinations, rapid heart rate, fever).,Store securely out of reach of children; dispose of unused medication properly.,Contact your doctor if pain persists or worsens after a few days.
Take AMRIX exactly once daily at the same time each day; do not crush, chew, or open the capsule.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase the risk of severe drowsiness and dizziness.,Do not drive or operate heavy machinery until you know how AMRIX affects you; it may cause drowsiness, dizziness, or blurred vision.,Contact your healthcare provider if you experience symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness, nausea, diarrhea).,Do not use AMRIX for longer than 2-3 weeks unless specifically directed by your doctor; prolonged use is not recommended.,Inform your doctor if you have a history of urinary retention, glaucoma, thyroid disorders, heart problems, or liver disease.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not double the dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORLEX vs AMRIX, answered by our medical review team.
ORLEX is a Muscle relaxant that works by Orlistat is a reversible inhibitor of gastric and pancreatic lipases, preventing the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. This reduces dietary fat absorption by approximately 30%.. AMRIX is a Muscle Relaxant that works by Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORLEX and AMRIX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORLEX is: Orally, 1-2 tablets (5-10 mg of hydrocodone equivalent) every 4-6 hours as needed for pain; maximum 12 tablets per day.. The standard adult dose of AMRIX is: 15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORLEX and AMRIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORLEX is classified as Category C. ORLEX (codeine/acetaminophen) is contraindicated in all trimesters due to risk of neonatal opioid withdrawal syndrome and acetaminophen hepatotoxicity. First trimester: limited dat. AMRIX is classified as Category C. Cyclobenzaprine (AMRIX) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but adequate well-controlled studies in pregnant women are lacki. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.